Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

By sjmartinez • September 22, 2022

Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Rivas JL, Yndestad A, Connell CA, Szekanecz Z. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2022 Sep 22:annrheumdis-2022-222259. doi: 10.1136/ard-2022-222259. Epub ahead of print. PMID: 36137735.

Tags: Antirheumatic Agents, Arthritis, cardiovascular diseases, Publications, Rheumatoid, Rheumatology, Therapeutics

Engineering an in vivo charging station for CAR-redirected invariant natural killer T cells to enhance cancer therapy

Li YR, Nan H, Liu Z, Fang Y, Zhu Y, Lyu Z, Shao Z, Zhu E, Zhang B, Yang Y, Shen X, Chen Y, Hsiai[...]

JPEN Journal Club 99. ICEMAN analyses

Koretz RL. JPEN Journal Club 99. ICEMAN analyses. JPEN J Parenter Enteral Nutr. 2026 Mar 17. doi: 10.1002/jpen.70072. Epub ahead of print. PMID: 41846318.

A Double-blind Randomized Trial of Oral Chlorhexidine Gluconate for Treatment of Oral Staphylococcus aureus Colonization in Healthy Children

Liu L, Launer B, Flores E, Tchakalian G, Kreiswirth B, Bolaris M, Kim T, Young KD, Miller LG. A Double-blind Randomized Trial of Oral Chlorhexidine[...]